The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Cécile Dorange

Showing 1-12 of 12 articles
The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled
Abizaid A, Costa Jr J, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong W-F, Sudhir K, Serruys P
April 20, 2015 | 10.4244/EIJV10I12A243
Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial
Bourantas C, Farooq V, Zhang Y-J, Muramatsu T, Gogas B, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia H, Serruys P
March 20, 2015 | 10.4244/EIJY14M04_11
Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)
Simsek C, Magro M, Onuma Y, Boersma E, Smits P, Dorange C, Veldhof S, Regar E, Serruys P, van Geuns R
June 20, 2014 | 10.4244/EIJV10I2A38
Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months
Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J
March 20, 2014 | 10.4244/EIJV9I11A217
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials
Gogas B, Bourantas C, Garcia-Garcia H, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns R, De Bruyne B, Chevalier B, Thuesen L, Smits P, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston J, Serruys P
October 25, 2013 | 10.4244/EIJV9I6A115
Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study
Gomez-Lara J, Diletti R, Brugaletta S, Onuma Y, Farooq V, Thuesen L, McClean D, Koolen J, Ormiston J, Windecker S, Whitbourn R, Dudek D, Dorange C, Veldhof S, Rapoza R, Regar E, Garcia-Garcia H, Serruys P
June 27, 2012
Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study
Brugaletta S, Garcia-Garcia H, Diletti R, Gomez-Lara J, Garg S, Onuma Y, Shin E, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Dorange C, Veldhof S, Rapoza R, Sudhir K, Bruining N, Ormiston J, Serruys P
April 20, 2011
Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial
Khattab A, Richardt G, Verin V, Kelbæk H, Macaya C, Berland J, Miquel-Hebert K, Dorange C, Serruys P
March 20, 2008
One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study
Ruygrok P, Desaga M, Van den Branden B, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys P
November 20, 2007
Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial)
Beijk M, Neumann F, Wiemer M, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys P, Piek J
August 20, 2007
Prospective non-randomized multi-center evaluation of the non-polymer based ACHIEVE™ Paclitaxel Eluting Coronary Stent System in treatment of lesions with high risk of revascularization due to restenosis: the DELIVER II study
Grube E, Gershlick A, Bartorelli A, Buellesfeld L, Blanchard D, Macaya C, Buettner H, Lim V, Boone E, Dorange C, Marco J
February 20, 2006
One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings<br />(The SPIRIT FIRST Trial)
Tsuchida K, Piek J, Neumann F, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys P
November 20, 2005

Latest news

NEW ISSUE
Robotics, AI and Imaging State of The Art; Bleeding Risk and Mortality in CAD; Treating Refractory Angina by Coronary Sinus Narrowing; and more
September 20, 2021
STATE OF THE ART
Robotics, imaging, and artificial intelligence in the catheterisation laboratory
Rafael Beyar et al.
September 20, 2021
AHEAD OF PRINT
ViV TAVI vs repeat SAVR
Monil Majmundar et al.
September 15, 2021
AHEAD OF PRINT
Thrombectomy for ischaemic stroke
Christopher A. Rajkumar et al.
September 10, 2021
EDITORIAL
Walking the tightrope between ischaemia and bleeding
Michelle L. O’Donoghue et al.
September 20, 2021
EDITORIAL
Microvascular dysfunction endotypes and outcomes
Christos V. Bourantas et al.
September 20, 2021
EDITORIAL
Coronary sinus reducer therapy for refractory angina: is it ready for prime time?
Michael Foley et al.
September 20, 2021
Coronary
Valvular disease
Heart failure
Peripheral
Hypertension
Stroke